In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enzon Pharmaceuticals, Inc.

http://enzon.com/

Latest From Enzon Pharmaceuticals, Inc.

Rovi’s Value-Added US Risperidone Gets New Goal Date, Teva Ruled Out As Partner

Spain’s Laboratorios Farmacéuticos Rovi has a firm date to remedy issues observed in its application for a hybrid version of risperidone, developed using Rovi’s proprietary ISM drug-release technology platform.

Value-Added Medicines Complete Response Letters

Deals In 2023: Partnerships And Modest M&A

Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.

Growth Deals

'Pivotal Time For CROs': ICON CEO Cutler On Changing APAC Trial Trends

The CEO of one the global top-five CROs points out a larger opportunity in decentralized trials that might be a “game changer” in the global pharma industry over the next five years. He also refers to the need to accept new technologies by both clinical trial sites and regulators.

Asia Pacific Clinical Trials

Multiple Agreements At Adalvo As Company Expects To File 30 DCPs This Year

Alvo group B2B unit Adalvo expects to file 30 decentralized procedures in Europe over the coming year as it expands its partnerships with Frontier Biopharma, Zentiva and Stada.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
UsernamePublicRestriction

Register